Petros Pharmaceuticals, Inc. (PTPI) — 10-Q Filings

10-Q Filings (6)

• Petros Pharma Swings to Profit on Asset Sales, Shifts to OTC Tech — Nov 13, 2025 Risk: high
  Petros Pharmaceuticals, Inc. reported a net income of $2,250,101 for the nine months ended September 30, 2025, a significant improvement from a net loss of $5,0
• Petros Pharma Pivots to OTC Tech, Posts Q2 Profit on Asset Sales — Aug 14, 2025 Risk: high
  Petros Pharmaceuticals, Inc. (PTPI) reported a significant turnaround in net income, reaching $3,172,824 for the six months ended June 30, 2025, compared to a n
• Petros Pharma 10-Q: Warrant Fair Value Inputs Detailed — May 15, 2025 Risk: medium
  Petros Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information, including fair value adjustments for
• Petros Pharmaceuticals Files Q3 2024 10-Q — Nov 13, 2024 Risk: medium
  Petros Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates. Key fina
• Petros Pharma Files Q2 2024 10-Q — Aug 14, 2024 Risk: medium
  Petros Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the second
• Petros Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024 — May 15, 2024 Risk:
  Petros Pharmaceuticals, Inc. (PTPI) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Petros Pharmaceuticals, Inc. filed a 10-Q report for the perio

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX